Lexicon Income Tax Expense from 2010 to 2024

LXRX Stock  USD 0.80  0.02  2.44%   
Lexicon Pharmaceuticals Income Tax Expense yearly trend continues to be fairly stable with very little volatility. Income Tax Expense is likely to outpace its year average in 2024. During the period from 2010 to 2024, Lexicon Pharmaceuticals Income Tax Expense regression line of annual values had significance of  0.58 and arithmetic mean of  260,101. View All Fundamentals
 
Income Tax Expense  
First Reported
2000-03-31
Previous Quarter
-3 M
Current Value
100.7 K
Quarterly Volatility
11.5 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Lexicon Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lexicon Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 526.3 K, Interest Expense of 13.8 M or Total Revenue of 1.1 M, as well as many indicators such as Price To Sales Ratio of 209, Dividend Yield of 0.0 or PTB Ratio of 5.52. Lexicon financial statements analysis is a perfect complement when working with Lexicon Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Lexicon Pharmaceuticals Correlation against competitors.
For more information on how to buy Lexicon Stock please use our How to Invest in Lexicon Pharmaceuticals guide.

Latest Lexicon Pharmaceuticals' Income Tax Expense Growth Pattern

Below is the plot of the Income Tax Expense of Lexicon Pharmaceuticals over the last few years. It is Lexicon Pharmaceuticals' Income Tax Expense historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lexicon Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Income Tax Expense10 Years Trend
Pretty Stable
   Income Tax Expense   
       Timeline  

Lexicon Income Tax Expense Regression Statistics

Arithmetic Mean260,101
Coefficient Of Variation2,083
Mean Deviation3,470,494
Median386,105
Standard Deviation5,418,589
Sample Variance29.4T
Range24.3M
R-Value0.15
Mean Square Error30.9T
R-Squared0.02
Significance0.58
Slope187,766
Total Sum of Squares411.1T

Lexicon Income Tax Expense History

2024405.4 K
2023386.1 K
20221.2 M
2021510 K
202011.6 M
2019-6 M
20183.5 M

About Lexicon Pharmaceuticals Financial Statements

Lexicon Pharmaceuticals investors use historical fundamental indicators, such as Lexicon Pharmaceuticals' Income Tax Expense, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Lexicon Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Income Tax Expense386.1 K405.4 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Lexicon Stock Analysis

When running Lexicon Pharmaceuticals' price analysis, check to measure Lexicon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceuticals is operating at the current time. Most of Lexicon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexicon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lexicon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.